NextCure Statistics
Total Valuation
NextCure has a market cap or net worth of $43.43 million. The enterprise value is $5.76 million.
Important Dates
The last earnings date was Thursday, March 5, 2026, after market close.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NextCure has 3.51 million shares outstanding. The number of shares has increased by 21.97% in one year.
| Current Share Class | 3.51M |
| Shares Outstanding | 3.51M |
| Shares Change (YoY) | +21.97% |
| Shares Change (QoQ) | +48.77% |
| Owned by Insiders (%) | 1.26% |
| Owned by Institutions (%) | 22.50% |
| Float | 2.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.24 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.14, with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.14 |
| Quick Ratio | 3.96 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -111.23% and return on invested capital (ROIC) is -65.17%.
| Return on Equity (ROE) | -111.23% |
| Return on Assets (ROA) | -54.96% |
| Return on Invested Capital (ROIC) | -65.17% |
| Return on Capital Employed (ROCE) | -145.43% |
| Weighted Average Cost of Capital (WACC) | 11.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.30M |
| Employee Count | 43 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.92% in the last 52 weeks. The beta is 1.55, so NextCure's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | +35.92% |
| 50-Day Moving Average | 12.65 |
| 200-Day Moving Average | 8.60 |
| Relative Strength Index (RSI) | 47.98 |
| Average Volume (20 Days) | 41,842 |
Short Selling Information
The latest short interest is 61,725, so 1.76% of the outstanding shares have been sold short.
| Short Interest | 61,725 |
| Short Previous Month | 47,514 |
| Short % of Shares Out | 1.76% |
| Short % of Float | 3.08% |
| Short Ratio (days to cover) | 1.92 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -57.62M |
| Pretax Income | -55.84M |
| Net Income | -55.84M |
| EBITDA | -55.43M |
| EBIT | -57.62M |
| Earnings Per Share (EPS) | -$19.65 |
Full Income Statement Balance Sheet
The company has $41.82 million in cash and $4.15 million in debt, with a net cash position of $37.67 million or $10.75 per share.
| Cash & Cash Equivalents | 41.82M |
| Total Debt | 4.15M |
| Net Cash | 37.67M |
| Net Cash Per Share | $10.75 |
| Equity (Book Value) | 34.94M |
| Book Value Per Share | 9.97 |
| Working Capital | 33.18M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -49.61M |
| Capital Expenditures | n/a |
| Free Cash Flow | -49.61M |
| FCF Per Share | -$14.15 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NextCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.97% |
| Shareholder Yield | -21.97% |
| Earnings Yield | -128.57% |
| FCF Yield | -114.22% |
Analyst Forecast
The average price target for NextCure is $23.00, which is 90.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $23.00 |
| Price Target Difference | 90.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -54.06% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jul 14, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |